{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039445","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.137406+00:00","generated_at":"2026-06-08T21:29:58.693271+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus presents Phase 1 Decoy20 interim data: stable disease in all 4 patients","bullets":["All four patients in first cohort showed stable disease at 4 weeks; three had progressive disease at baseline.","Decoy20 induced transient expression of over 50 biomarkers associated with innate/adaptive anti-tumor immune responses.","Adverse events generally tolerable, resolved within 30 minutes to 3 days; drug cleared from blood in 30-120 minutes.","Peak cytokine/chemokine induction ~4-24 hours, returning to baseline by 24-48 hours, avoiding prolonged toxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039445","json":"https://secwatch.observer/filing/0001493152-23-039445.json","markdown":"https://secwatch.observer/filing/0001493152-23-039445.md","text":"https://secwatch.observer/filing/0001493152-23-039445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223039445/0001493152-23-039445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223039445/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:29:58.693271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}